AB2 Bio received $30 million from Nippon Shinyaku, which exercised its exclusive U.S. commercialization option for Tadekinig alfa, a treatment for Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome, a rare pediatric disease with no FDA-approved therapies. AB2 Bio retains global rights outside the U.S. and for other indications, with potential milestone and royalty payments up to $600 million. The companies aim to accelerate U.S. patient access while AB2 Bio leads regulatory filings. This deal marks a key step toward addressing a critical unmet medical need in ultra-rare inflammatory diseases.
eSUN has introduced PLA-Coffee, a new 3D printing filament combining recycled coffee grounds with biodegradable PLA. This innovation supports sustainability by repurposing organic waste and reducing plastic carbon footprints. The filament offers a un...
On July 30, 2026, Michelin executed a share buyback program, purchasing 193,528 ordinary shares at an average price of €33.82 per share. The shares were bought over-the-counter through brokers Natixis, BNP Paribas, and Societe Generale. The purpose o...
Renault SA announced the release of its financial report for the first half of 2026 on July 30, 2026. The report is available on Renault's investor website and highlights the company's robust revenue growth driven by both its automotive and other bus...
Renault SA announced that it has filed its 2026 Half-Year Financial Report with the French Financial Markets Authority on July 30, 2026. The report is accessible on Renault's official website under the 'Investors' section in 'Regulated information.' ...
Atos Group released its half-year financial report for 2026, showing a strong performance in the first half of the year. The company highlighted sustained delivery of its services and remains confident about achieving its full-year financial targets....
